Tg therapeutics, inc. (TGTX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Mar'12Dec'11
CASH FLOWS FROM OPERATING ACTIVITIES
Consolidated net loss

-172,871

-173,482

-118,476

-78,253

-62,948

-55,781

-20,478

-26,182

-18,285

-889

Adjustments to reconcile net loss to net cash used in operating activities:
Gain on settlement of notes payable

-

-

-

-

-

95

0

-

-

-

Gain on sale of long-term securities

-

-

-

-33

0

0

-

-

-

-

Recognized stock based compensation expense

11,335

12,886

15,945

7,510

-

-

-

-

-

-

Non-cash stock compensation expense

-

-

-

-

15,697

21,105

5,203

3,422

275

86

Shares issued in connection with in-licensing agreement

100

4,000

0

0

-

5,350

0

16,578

16,875

-297

Impairment of in-process research and development

-

-

-

-

-

-

2,797

1,104

-

0

Depreciation and amortization

100

88

82

63

15

3

1

0

-

0

Amortization of premium on investment securities

257

119

61

459

536

193

0

0

-

-

Amortization of debt issuance costs

800

0

0

-

-

-

-

-

-

-

Amortization of leasehold interest

182

135

125

-

-

-

-

-

-

-

Non-cash change in lease liability and right-of-use asset

2,519

0

0

-

-

-

-

-

-

-

Change in fair value of notes payable

-124

61

-59

110

56

-210

2,414

815

-

0

Changes in assets and liabilities:
Increase in restricted cash

-

-

-

-

4

575

0

-

-

-

Increase in other current assets

-1,395

1,638

2,665

-3,565

3,105

4,563

-229

1,932

-

-3

Decrease (increase) in leasehold interest

-

-

-

-2,042

0

0

-

-

-

-

Increase in accrued interest receivable

11

-14

25

-102

100

58

27

0

-

-

Decrease in other assets

0

0

-162

5

41

0

0

0

-

-

Decrease in other current assets

-

-

-

-

-

-

-

-

-11

-

(Decrease) increase in accounts payable and accrued expenses

-4,795

10,957

11,020

6,493

5,470

-603

4,034

595

153

408

Decrease in lease liabilities

-1,548

0

0

0

-

-

-

-

-

-

(Decrease) increase in interest payable

1,491

0

0

-

-

-94

66

61

21

7

Decrease in other liabilities

28,810

18,350

0

-

-

-

-

-

-

-

Increase in deferred rent

0

-97

-104

816

0

0

-

-

-

-

Decrease in deferred revenue

-152

-152

-152

-152

-152

-152

-152

1,980

-

0

Net cash used in operating activities

-132,806

-128,925

-93,760

-

-

-

-

-

-948

-86

Net cash used in operating activities

-

-

-

-61,587

-44,690

-35,059

-10,739

-5,187

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from maturity of short-term securities

29,250

32,500

19,800

29,500

24,350

0

0

-

-

-

Investment in held-to-maturity long-term securities

-

-

-

-

-

-

-

0

-

-

Investment in held-to-maturity securities

29,837

31,230

28,006

15,200

48,993

18,336

4,919

-

-

-

Purchases of equipment

131

90

2

344

42

18

5

1

-

0

Proceeds from the sale of long-term securities

-

-

-

12,589

0

0

-

-

-

-

Cash acquired in connection with acquisition

-

-

-

-

-

-

-

0

10

10

Net cash provided by (used in) investing activities

-718

1,180

-8,208

-

-

-

-

-

10

10

Net cash (used in) provided by investing activities

-

-

-

26,545

-24,685

-18,355

-4,925

-1

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of options

-

-

-

-

-

202

0

-

-

-

Payment of notes payable

-

-

-

-

-

677

0

-

-

-

Proceeds from sale of common stock, net

175,021

113,639

131,516

4,411

67,760

65,614

37,648

-

-

-

Proceeds from exercise of options

0

0

2,143

618

1,067

3,556

2,280

0

-

-

Proceeds from debt financings

29,987

0

0

-

-

-

-

-

-

-

Financing costs paid

795

0

0

13

104

51

85

-

-

-

Payments of short-term loans

-

-

-

-

-

-

-

200

200

0

Proceeds from sale of common stock, net

-

-

-

-

-

-

-

0

9,824

9,824

Proceeds from sale of preferred stock, net

-

-

-

-

-

-

-

12,257

12,257

0

Offering costs paid

-

-

-

-

-

-

-

75

20

0

Purchase of treasury stock

-

-

-

-

-

-

149

84

-

0

Net cash provided by financing activities

-

-

-

5,016

68,723

68,643

39,694

11,896

-

-

Net cash provided by financing activities

204,213

113,639

133,659

-

-

-

-

-

21,861

9,824

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

70,689

-14,106

31,691

-30,026

-652

15,228

24,029

6,707

20,923

9,748

NONCASH TRANSACTIONS
Reclassification of deferred financing costs to additional paid-in capital

-

-

-

-25

-111

0

0

-

-

-

Conversion of convertible notes payable to common stock

-

-

-

33

6

0

0

-

-

-

Conversion of notes payable to preferred stock

-

-

-

-

-

-

-

0

55

55

Deferred financing costs

-

-

-

-

-

-

-

0

116

61